Skip to content
Medical Health Aged Care, National News Current Affairs

The Duchess of York’s breast cancer diagnosis is an important reminder to gets your breasts checked

Breast Cancer Network Australia 2 mins read

At Breast Cancer Network Australia (BCNA) we know that when a public figure is diagnosed with breast cancer it may be very disconcerting and can affect people in many different ways.

We were very sorry to hear that the Duchess of York, Sarah Ferguson has recently been diagnosed with an early form of breast cancer, detected through a routine mammogram, and has recently undergone surgery. We are happy to hear she is now recuperating with her family.

The risk of being diagnosed with breast cancer over a lifetime is 1 in 7 for women and 1 in 555 for men. The benefits of early detection include increased survival rates, increased treatment options and improved quality of life post diagnosis.

BCNA’s Director of Policy, Advocacy and Support Services Vicki Durston reminds women over 40 who do not have any breast cancer symptoms that they are entitled to a free mammogram every two years through BreastScreen.


‘After Covid there was a 9% national decline in participation rates for breast screening, so this is an important reminder of the importance of screening and early detection’ Ms Durston says.

Even if you are having regular screening mammograms, you should still see your doctor if you notice any change in your breasts. For those at increased risk or at very high-risk of developing breast cancer, a more tailored screening program can be offered and is best discussed with your GP.

If hearing this news has been hard for you, our Helpline can offer support and recommend the most appropriate resources for you - 1800 500 258.

About us:

Breast Cancer Network Australia (BCNA) is Australia’s leading breast cancer consumer organisation. BCNA provides information and support to those diagnosed and their supporters, opportunities to connect with others going through a similar situation and work to influence a stronger healthcare system to ensure all Australians affected by breast cancer receive the very best care, treatment and support.

Contact details:

Sophie Findlay

Media & Marketing Coordinator

0426 114 331


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.